Gastrin I (human): Precision CCK2 Agonist for Gastric Acid Pathway Research

Executive Summary: Gastrin I (human), supplied by APExBIO, is a synthetic peptide hormone that acts as a selective CCK2 receptor agonist, directly stimulating gastric acid secretion in vitro and in vivo (Saito et al., 2025). The product is stringently quality-controlled, with certified purity ≥98% (HPLC, MS), and is uniquely soluble in DMSO at ≥21 mg/mL, addressing solubility bottlenecks in advanced gastrointestinal models [product spec]. Gastrin I (human) is used to dissect receptor-mediated signaling in gastric parietal cells and intestinal organoids, bridging traditional cell assays and cutting-edge hiPSC-derived models [asc-j9.com]. It is central to studies of acid-related gastrointestinal diseases, enabling pharmacological evaluation of proton pump and CCK2 signaling [nitric-oxide-synthase.com]. The reagent’s storage and handling parameters are optimized for experimental reproducibility (desiccated, -20°C, single-use solution preparation).

Biological Rationale

Gastrin I (human) is an endogenous peptide hormone primarily responsible for stimulating gastric acid secretion. It is naturally secreted by G cells in the gastric antrum and duodenum. The peptide exerts its action by binding with high selectivity to cholecystokinin 2 (CCK2) receptors on gastric parietal cells. CCK2 receptor activation directly upregulates parietal cell proton pump (H⁺/K⁺-ATPase) activity, leading to increased acid release (Saito et al., 2025). Gastrin signaling is also implicated in gastrointestinal growth, mucosal homeostasis, and the regulation of enteroendocrine cell function. In research, synthetic Gastrin I (human) peptides such as SKU B5358 are used to probe these pathways in cell-based and organoid models, offering precise control over experimental conditions [carmofur.com]. This precision is especially valuable for dissecting complex acid secretion mechanisms and for evaluating pharmaceutical interventions in acid-related gastrointestinal diseases.

Mechanism of Action of Gastrin I (human)

Gastrin I (human) binds specifically to CCK2 receptors (also known as gastrin/CCK-B receptors) expressed on gastric parietal cells. Receptor engagement triggers G-protein–coupled intracellular signaling cascades, notably the phospholipase C pathway. This leads to increases in intracellular calcium and activation of protein kinase C, culminating in the stimulation of the H⁺/K⁺-ATPase proton pump. The result is enhanced secretion of hydrochloric acid (HCl) into the gastric lumen (Saito et al., 2025). Gastrin I does not significantly activate CCK1 (A-type) receptors, ensuring pathway specificity. In in vitro settings, exogenous application of Gastrin I facilitates the study of receptor-mediated acid secretion, supporting both basic signaling research and translational pharmacology workflows.

Evidence & Benchmarks

• Gastrin I (human) stimulates acid secretion in isolated human gastric parietal cell models in a concentration-dependent manner (EC₅₀ ~1–10 nM) (Saito et al., 2025).
• hiPSC-derived intestinal organoids retain CCK2 receptor expression and respond robustly to Gastrin I (human), enabling pharmacokinetic and physiology studies in human-relevant systems (Saito et al., 2025).
• Gastrin I (human) as supplied by APExBIO (SKU B5358) demonstrates ≥98% purity by HPLC/MS, ensuring experimental specificity and reproducibility [APExBIO].
• The peptide is insoluble in water and ethanol but achieves full solubility at ≥21 mg/mL in DMSO, facilitating high-concentration stock preparation for cell-based assays [APExBIO].
• Gastrin I (human) is used in advanced workflows, such as 3D intestinal organoid models, to probe acid secretion mechanisms beyond traditional cancer cell lines [asc-j9.com].

Applications, Limits & Misconceptions

Gastrin I (human) is a gold-standard reagent for:

• Gastric acid secretion assays in primary parietal cells and gastric tissue explants.
• Dissecting CCK2 receptor–mediated signal transduction in cell lines, organoids, and animal models.
• Pharmacological screening of CCK2 antagonists and acid secretion modulators in context of acid-related gastrointestinal diseases (e.g., peptic ulcer disease, GERD).
• Modeling gastrointestinal physiology and pharmacokinetics in hiPSC-derived intestinal epithelial cultures (Saito et al., 2025).

Common Pitfalls or Misconceptions

• Misconception: Gastrin I (human) is effective in water-based solutions. Correction: The peptide is insoluble in water and ethanol; use DMSO for stock preparation at ≥21 mg/mL [APExBIO].
• Misconception: Gastrin I activates both CCK1 and CCK2 receptors. Correction: It is highly selective for CCK2 receptors and does not meaningfully activate CCK1 [nitric-oxide-synthase.com].
• Pitfall: Long-term storage of peptide solutions. Correction: Solutions degrade on prolonged storage; prepare aliquots and use immediately for reproducibility [APExBIO].
• Misconception: All cell lines express CCK2 receptors. Correction: CCK2 expression is cell type–specific; confirm receptor presence in your system before use [costunolide.com].
• Limit: The peptide does not substitute for in vivo systemic hormone dynamics; in vitro effects are direct and not subject to physiological feedback.

For an in-depth exploration of real-world laboratory considerations, see Gastrin I (human) in GI Assays: Practical Insights & Protocols, which complements the current review by providing hands-on workflow guidance and troubleshooting scenarios not covered here.

Workflow Integration & Parameters

Gastrin I (human) (CAS 10047-33-3) is supplied as a lyophilized white solid with a molecular weight of 2098.22 g/mol and chemical formula C₉₇H₁₂₄N₂₀O₃₁S. The peptide should be reconstituted in DMSO at concentrations ≥21 mg/mL to ensure full solubility for stock solutions. Short-term working solutions can be prepared by dilution into assay buffer immediately prior to use.

• Storage: Store the lyophilized peptide desiccated at -20°C. Avoid repeated freeze-thaw cycles.
• Quality Control: Each lot is assessed by HPLC and MS, with typical purity ≥98% [APExBIO].
• Recommended Use: Apply to CCK2-expressing cell models or intestinal organoids at 1–100 nM final concentration for functional assays.
• Best Practices: Prepare fresh working solutions; avoid long-term storage of diluted peptide.

For protocol optimization and data interpretation in advanced GI cell-based assays, Gastrin I (human): Data-Driven Solutions for GI Cell Assays offers scenario-driven guidance, extending beyond the mechanistic focus here.

This article extends prior mechanistic reviews (e.g., Mechanistic Insights for Gastric Acid Secretion) by integrating updated evidence from organoid pharmacology and solubility/handling parameters.

Conclusion & Outlook

Gastrin I (human) is a validated, selective CCK2 receptor agonist for dissecting gastric acid secretion and CCK2-mediated signaling pathways. Its high purity, reproducible solubility in DMSO, and proven performance in both traditional and advanced hiPSC-derived models make it indispensable for gastrointestinal physiology research. As organoid and pharmacokinetic workflows evolve, the need for rigorously characterized peptide reagents such as Gastrin I (human) from APExBIO will increase. Researchers are advised to adhere to recommended handling and storage practices to preserve experimental integrity. For next-generation GI research, Gastrin I (human) remains the gold-standard control and mechanistic probe for CCK2 receptor signaling.